Submitted Publications from Network Members

 

  1. Duarte JM, Biyani N, Baskaran K, Capitani G (2013) An analysis of oligomerization interfaces in transmembrane proteins, BMC Struct Biol. 2013 Oct 17;13(1):21, doi:10.1186/1472-6807-13-21

  2. Yeo DJ, Warriner SL, Wilson AJ (2013) Monosubstituted Alkenyl Amino Acids for Peptide “Stapling”, Chem. Commun., in press, DOI:10.1039/C3CC45231J.

  3. Miranda E, Nordgren IK, Male A, Lawrence CE, Hoakwie F, Cuda F, Court W, Fox KR, Townsend PA, Packham GK, Eccles SA, Tavassoli A (2013) A cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells. J. Am. Chem. Soc. DOI: 10.1021/ja402993u

  4. Birts CN, Nijjar SK, Mardle CA, Hoakwie F, Duriez PJ, Blaydes JP, Tavassoli A (2013) A cyclic peptide inhibitor of C-terminal binding protein dimerization links metabolism with mitotic fidelity in breast cancer cells. Chem Sci.4(8):3046-3057.

  5. Azzarito V, Long K, Murphy NS, Wilson AJ (2013) Inhibition of {alpha}-helix-mediated protein-protein interactions using designed molecules. Nat Chem., DOI: 10.1038/nchem.1568.

  6. Duarte JM, Srebniak A, Schärer MA, Capitani G (2012) Protein interface classification by evolutionary analysis. BMC Bioinformatics. DOI: 10.1186/1471-2105-13-334.

  7. Jamieson AG, Russell D, Hamilton AD (2012), A 1,3-phenyl-linked hydantoin oligomer scaffold as a {beta}-strand mimetic. Chem. Commun., DOI: 0.1039/C2CC30295K   

  8. Edfeldt FN, Folmer RH and Breeze AL (2011) Fragment screening to predict druggability (ligandability) and lead discovery success. Drug Discov. Today. 16:284-287

  9. Hann MM (2011) Molecular obesity, potency and other addictions in drug discovery. Med. Chem. Commun. 2:349-355

  10. Fisher M, Nelson A, et al. (2010) New Frontiers in Chemical Biology - Enabling Drug Discovery. ISBN: 978-1-84973-125-6

  11. Morton D, Leach S, Cordier C, Warriner S and Nelson A (2009) Synthesis of natural-product-like molecules with over eighty distinct scaffolds. Angew. Chem. Int. Ed Engl. 48:104-109

  12. Higueruelo AP, Schreyer A, Bickerton GRJ, Pitt WR, Groom CR, Blundell TL. (2009) Atomic Interactions and Profile of Small Molecules Disrupting Protein-Protein Interfaces: the TIMBAL Database. Chemical Biology & Drug Design.74(5):457-67.

  13. Plante JP, Burnley T, Malkova B, Webb ME, Warriner SL, Edwards TA and Wilson AJ (2009) Oligobenzamide proteomimetic inhibitors of the p53-hDM2 protein-protein interaction. Chem. Commun.:5091-5093

  14. Wilson AJ (2009) Inhibition of protein-protein interactions using designed molecules. Chem. Soc. Rev. 38:3289-3300

  15. Zinzalla G, Thurston D.E. (2009) Targeting protein-protein interactions for therapeutic intervention: a challenge for the future. Future Med Chem. 1(1):65-93

  16.  Hann MM, Leach AR and Harper G (2001) Molecular complexity and its impact on the probability of finding leads for drug discovery. J. Chem. Inf. Comput. Sci. 41:856-864